Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immucell (ICCC) Net Margin (2016 - 2025)

Immucell (ICCC) has disclosed Net Margin for 16 consecutive years, with 2.54% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin rose 1028.0% year-over-year to 2.54%, compared with a TTM value of 8.37% through Sep 2025, up 2870.0%, and an annual FY2024 reading of 8.14%, up 2491.0% over the prior year.
  • Net Margin was 2.54% for Q3 2025 at Immucell, down from 7.79% in the prior quarter.
  • Across five years, Net Margin topped out at 17.94% in Q1 2025 and bottomed at 67.17% in Q1 2023.
  • Average Net Margin over 5 years is 11.69%, with a median of 8.39% recorded in 2021.
  • The sharpest move saw Net Margin crashed -7943bps in 2023, then surged 6114bps in 2024.
  • Year by year, Net Margin stood at 1.36% in 2021, then tumbled by -3232bps to 42.65% in 2022, then skyrocketed by 59bps to 17.42% in 2023, then surged by 138bps to 6.64% in 2024, then crashed by -138bps to 2.54% in 2025.
  • Business Quant data shows Net Margin for ICCC at 2.54% in Q3 2025, 7.79% in Q2 2025, and 17.94% in Q1 2025.